Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.

Guo X, Li T, Li F, Xu Y, Wang H, Cheng W, Tang J, Zhou G, Chen H, Ng M, Ji M, Ge S, Xia N.

Oral Oncol. 2019 Jun;93:85-90. doi: 10.1016/j.oraloncology.2019.04.024. Epub 2019 Apr 30.

PMID:
31109701
2.
3.

Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.

Ramayanti O, Juwana H, Verkuijlen SA, Adham M, Pegtel MD, Greijer AE, Middeldorp JM.

Int J Cancer. 2017 Jan 1;140(1):149-162. doi: 10.1002/ijc.30418. Epub 2016 Sep 23.

4.

The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.

He YQ, Xue WQ, Xu FH, Xu YF, Zhang JB, Yu HL, Feng QS, Chen LZ, Cao SM, Liu Q, Mu J, Zeng YX, Jia WH.

EBioMedicine. 2018 Apr;30:184-191. doi: 10.1016/j.ebiom.2018.02.019. Epub 2018 Feb 23.

5.

[Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].

Cai YL, Zheng YM, Cheng JR, Wang W, Zhang YN, Wang WH, Wu YS, Zhong WM, Li J, Mo YK.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Mar;30(3):509-11. Chinese.

PMID:
20335122
6.

Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China.

Zhou T, Yang DW, He YQ, Xue WQ, Liao Y, Zheng MQ, Jia YJ, Yuan LL, Zhang WL, Zeng YX, Jia WH.

Cancer Med. 2019 Aug;8(10):4852-4866. doi: 10.1002/cam4.2348. Epub 2019 Jun 26.

8.

Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.

Liu MY, Huang YT, Sheen TS, Chen JY, Tsai CH.

J Med Virol. 2004 Aug;73(4):574-82.

PMID:
15221902
9.

Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.

Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, Zhou GQ, Cheng ZB, Qi ZY, Sun Y.

Cancer Sci. 2017 Aug;108(8):1640-1647. doi: 10.1111/cas.13296. Epub 2017 Jul 13.

10.

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.

Cancer. 2004 Mar 15;100(6):1162-70.

11.

[Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].

Cai YL, Zheng YM, Wang W, Wei Y, Shen XX, Cheng JR, Wu YS, Gao JQ, Zhong WM, Li J.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Dec;30(12):2746-8. Chinese.

PMID:
21177196
12.

Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.

Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M.

Int J Cancer. 2012 Jul 15;131(2):406-16. doi: 10.1002/ijc.26380. Epub 2011 Nov 19.

13.

Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.

Cui J, Yan W, Xu S, Wang Q, Zhang W, Liu W, Ni A.

PLoS One. 2018 Mar 1;13(3):e0193171. doi: 10.1371/journal.pone.0193171. eCollection 2018.

14.

Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.

Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM.

J Med Virol. 2007 Nov;79(11):1710-21.

PMID:
17854043
15.

Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.

Chen Y, Xu Y, Zhao W, Xiao X, Zhou X, Lin L, Huang T, Liao J, Li Y, Zeng X, Huang G, Ye W, Zhang Z.

BMC Cancer. 2018 Feb 14;18(1):190. doi: 10.1186/s12885-018-4110-6.

16.

Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.

Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM.

J Infect Dis. 2004 Jul 1;190(1):53-62. Epub 2004 May 26.

PMID:
15195243
17.

Study on sero-diagnosis of nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein-Barr virus antigens.

Gu YL, Zhang CQ, Ng SP, Zong YS, Liang YJ, Chen YL.

Ai Zheng. 2003 Sep;22(9):903-6.

PMID:
12969518
18.

Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.

Feng P, Ren EC, Liu D, Chan SH, Hu H.

J Gen Virol. 2000 Oct;81(Pt 10):2417-23.

PMID:
10993929
19.

Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK.

Int J Cancer. 2012 Oct 15;131(8):1930-40. doi: 10.1002/ijc.27439. Epub 2012 Mar 8.

20.

Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.

Wu CC, Chuang HY, Lin CY, Chen YJ, Tsai WH, Fang CY, Huang SY, Chuang FY, Lin SF, Chang Y, Chen JY.

Mol Carcinog. 2013 Dec;52(12):946-58. doi: 10.1002/mc.21926. Epub 2012 May 29.

PMID:
22641235

Supplemental Content

Support Center